Technology | 2009.11.22
UPDATE 1-ImmunoGen licenses anti-cancer technology to Amgen - Reuters
| UPDATE 1-ImmunoGen licenses anti-cancer technology to Amgen Reuters Shares of the company closed at $8.04 Thursday on Nasdaq. (Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel) |
For more information, please visit
http://news.google.com/news/url?fd=R&sa=[...]CNESXhZKH6I1FA6DA5Dp5D1TGjHGSQ
